At Vail Health’s Learning Lab, ‘Purpose Professor’ Christine Whelan Shares How to Live a Good Life
(Vail Daily) At a recent Vail Health Learning Lab, Dr. Christine Whelan shared how daily choices shape purpose and improve well-being.
Vail Health Launches Study Investigating How to Expand Antidepressant Effects of Psilocybin
(Vail Daily) Psilocybin, the active psychedelic ingredient in magic mushrooms, has been proven to impact patients with depression positively. Vail Health’s OPTIMIZE study, which will administer doses of psilocybin to all 140 participants, aims to investigate how to predict and enhance this effect.
Hope, Hype, and Humility: Dr. Charles Raison Reflects on Psychedelics’, and Psychiatry’s, Wild Ride
(Psychedelic Alpha) Dr. Charles Raison has long held an interest in melding ancient practices with today’s mental health system, looking at how things like meditation and psychedelics might interface with modern psychiatry.
Vail Health’s Pioneering Study of Psilocybin’s Effects on Depression Kicks off Next Month
(Vail Daily) In April, Vail Health’s Behavioral Health Innovation Center will kick off the second of two studies aimed at targeting depression. The OPTIMIZE study will examine the impacts of psilocybin, the active ingredient in psychedelic mushrooms, on people with major depressive disorder.
What Experts Say About Taking Psilocybin as an Alternative Treatment for Depression
(CNN) For a good number of people antidepressants have been a blessing, at least at the beginning of treatment, but for up to a third of depressed patients, antidepressants fail to work at all, said Dr. Charles Raison.